Enterprise Value
48.88M
Cash
168.8M
Avg Qtr Burn
-10.98M
Short % of Float
3.29%
Insider Ownership
15.69%
Institutional Own.
64.97%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CTX-009 (DLL4 and VEGF-A bispecific antibody) Details Cancer, Biliary Tract Cancer | Phase 2/3 Data readout | |
CTX-009 (DLL4 and VEGF-A bispecific antibody) Details Cancer, Colorectal cancer | Phase 2 Data readout | |
CTX-471 (CD137 + PD-1) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
Phase 1 Initiation |